Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 9;10:19360. doi: 10.1038/s41598-020-76377-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Rivaroxaban treatment results in lower human thrombi in vitro. (A–F) Representative brightfield images after 4 min of whole blood perfusion from healthy volunteers. Whole blood was pre-treated with (A) saline/DMSO, (B) 100 µM aspirin, (C) 500 ng/mL rivaroxaban, (D) 10 ng/mL rivaroxaban, (E) 100 µM aspirin and 500 ng/mL rivaroxaban and (F) 100 µM aspirin and 10 ng/mL rivaroxaban. Bar = 25 µm. (G) Subtraction heatmap of normalised parameters (0–10). Parameters include platelet surface area coverage (%SAC), thrombus morphological score (0–5), multilayer score (0–3) and, contraction score (0–3). N = 14 (control), 5 (ASA), 5 (RIVA 500 ng/mL), 5 (RIVA 10 ng/mL), 5 (ASA + RIVA 500 ng/mL) and 5 (ASA + RIVA 10 ng/mL) per group *p < 0.05 vs. control, Kruskal–Wallis test.